Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Janocha, R"'
Background: Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::664356cc3b5f8f5ece5cfb74e382f61a
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999998
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999998
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maurer, M, Giménez-Arnau, A, Sussman, G, Metz, M, Bauer, A, Bernstein, J, Brehler, R, Chu, C-Y, Chung, W-H, Danilycheva, I, Grattan, C, Hebert, J, Katelaris, C, Makris, M, Meshkova, R, Savic, S, Sinclair, R, Sitz, K, Staubach, P, Wedi, B, Löffler, J, Barve, A, Kobayashi, K, Hua, E, Severin, T, Janocha, R
Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::8e562e5191721e1d1d274e96316f800c
https://eprints.whiterose.ac.uk/148925/1/nejmoa1900408.pdf
https://eprints.whiterose.ac.uk/148925/1/nejmoa1900408.pdf
Autor:
Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany., Giménez-Arnau A; Dermatology Department, Hospital del Mar, IMIM Universitat Autònoma Barcelona, Barcelona, Spain., Bernstein JA; University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio, USA., Chu CY; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Danilycheva I; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia., Hide M; Department of Dermatology, Hiroshima University, Hiroshima, Japan., Makris M; Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University, 'Attikon' University Hospital, Athens, Greece., Metz M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany., Savic S; Leeds Biomedical Research Centre, Department of Clinical Immunology and Allergy, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), St James's University Hospital, Leeds, UK., Sitz K; Little Rock Allergy and Asthma Clinic, Little Rock, Arkansas, USA., Soong W; Alabama Allergy & Asthma Center - AllerVie Health, Clinical Research Center of Alabama, Birmingham, Alabama, USA., Staubach P; Department of Dermatology, University Medical Center, Mainz, Germany., Sussman G; Division of Allergy and Clinical Immunology, University of Toronto, Canada., Barve A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Burciu A; Novartis Pharma AG, Basel, Switzerland., Hua E; China Novartis Institutes for Biomedical Research Co. Ltd, Shanghai, China., Janocha R; Novartis Pharma AG, Basel, Switzerland., Severin T; Novartis Pharma AG, Basel, Switzerland.
Publikováno v:
Allergy [Allergy] 2022 Jul; Vol. 77 (7), pp. 2175-2184. Date of Electronic Publication: 2021 Nov 22.
Autor:
Giménez-Arnau A; Department of Dermatology, Hospital del Mar, Institut Mar d´Investigacions Mèdiques, Universitat Autònoma, Barcelona, Spain., Maurer M; Department of Dermatology and Allergy, Dermatological Allergology, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany., Bernstein J; Bernstein Allergy Group and Bernstein Clinical Research Center, College of Medicine, Cincinnati, Ohio, USA., Staubach P; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Barbier N; Novartis Pharma AG, Basel, Switzerland., Hua E; China Novartis Institutes for Biomedical Research Co. Ltd, Shanghai, China., Severin T; Novartis Pharma AG, Basel, Switzerland., Joubert Y; Novartis Pharma AG, Basel, Switzerland., Janocha R; Novartis Pharma AG, Basel, Switzerland., Balp MM; Novartis Pharma AG, Basel, Switzerland.
Publikováno v:
Clinical and translational allergy [Clin Transl Allergy] 2022 Feb; Vol. 12 (2), pp. e12121.
Publikováno v:
In Annales de Dermatologie et de Vénéréologie December 2020 147(12) Supplement:A343-A344
Autor:
Soong, W., Bernstein, J.A., Sussman, G., Lanier, B., Sitz, K., Maurer, M., Gimenez Arnau, A.M., Hua, E., Barve, A., Severin, T., Janocha, R.
Publikováno v:
In Annales de Dermatologie et de Vénéréologie December 2020 147(12) Supplement:A344-A344
Autor:
Janocha, R., Giménez-Arnau, A., Maurer, M., Bernstein, J., Barbier, N., hua, E., Severin, T., Balp, M.
Publikováno v:
In Annals of Allergy, Asthma & Immunology November 2020 125(5) Supplement:S22-S23
Autor:
Bernstein, J., Maurer, M., Giménez-Arnau, A., Soong, W., Metz, M., Barbier, N., Barve, A., Severin, T., Balp, M., Janocha, R.
Publikováno v:
In Annals of Allergy, Asthma & Immunology November 2020 125(5) Supplement:S22-S22
Autor:
Severin, T., Soong, W., Maurer, M., Giménez-Arnau, A., Hide, M., Bernstein, J., Hua, E., Barve, A., Janocha, R.
Publikováno v:
In Annals of Allergy, Asthma & Immunology November 2020 125(5) Supplement:S13-S13